Opthea Appoints John Han, PharmD, as VP Medical Affairs
April 08, 2024 18:42 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference
April 04, 2024 18:34 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Appoints Sujal Shah to the Board of Directors
April 03, 2024 17:39 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
March 19, 2024 06:00 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to...
Opthea to Participate in the Leerink Partners Global Biopharma Conference
March 05, 2024 17:08 ET
|
Opthea Limited
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly...
Opthea Reports Half-Year Financial Results and Business Updates
February 28, 2024 17:55 ET
|
Opthea Limited
Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025 Expanded U.S. leadership team with the appointments of Dr....
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
February 19, 2024 18:25 ET
|
Opthea Limited
MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly...
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
February 14, 2024 07:00 ET
|
Opthea Limited
COAST trial is evaluating the superiority of sozinibercept combined with EYLEA® (aflibercept) over EYLEA alone in wet AMD Enrollment of second pivotal trial (ShORe) to complete in calendar Q2 2024 ...
Opthea Strengthens Team with Key Clinical and Regulatory Hires
February 01, 2024 06:00 ET
|
Opthea Limited
Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track record in products for retinal and ophthalmology...
Opthea to Receive US$35M Commitment and Additional US$50M Funding
December 27, 2023 06:00 ET
|
Opthea Limited
Opthea to receive remaining US$35m funding under the Development Funding Agreement (DFA) with Carlyle and its life science franchise Abingworth, as well as a further US$50m financing under an Amended...